₹179.1*
MRP ₹199
10% off
₹169.15*
MRP ₹199
15% CB
₹29.85 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Prescription drugWhats That
Composition :
FLUCONAZOLE-0.5% W/W
Manufacturer/Marketer :
Cosme Healthcare
Consume Type :
TOPICAL
Return Policy :
Not Returnable
Expires on or after :
Drug-Drug Interactions
No Drug - Drug interactions found in our data. We may lack specific data on this medicine and are actively working to update our database. Consult your doctor for personalized advice
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
No Drug - Food interactions found in our database. Some may be unknown. Consult your doctor for what to avoid during medication.
Drug-Food Interactions
Login/Sign Up
FLUCOS 150MG POWDER Substitute
ZOCON 0.05% GEL 15GM
by Others
₹3.00per tablet
Product Substitutes
Author Details
Drug-Diseases Interactions
FLUCONAZOLE-0.5% W/WOther diseases of liver
Severe
FLUCONAZOLE-0.5% W/WOther cardiac arrhythmias
Moderate
Drug-Diseases Interactions
Login/Sign Up
FLUCONAZOLE-0.5% W/WOther diseases of liver
Severe
How does the disease interact with Flucos 150mg Powder:
Hepatotoxicity has only sometimes been linked to the usage of Flucos 150mg Powder. There have been cases of reversible idiosyncratic hepatitis, cholestasis, and deadly fulminant hepatic failure; the latter generally affects people with substantial underlying medical disorders who are also taking several concurrent drugs. Patients with pre-existing hepatic problems should have periodic liver function tests done, especially during prolonged medication. If liver enzyme levels continue to rise or worsen, treatment should be stopped.
How to manage the interaction:
In patients with preexisting liver abnormalities, particularly during prolonged therapy, liver function tests should be done regularly. Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.
Hepatotoxicity has only sometimes been linked to the usage of Flucos 150mg Powder. There have been cases of reversible idiosyncratic hepatitis, cholestasis, and deadly fulminant hepatic failure; the latter generally affects people with substantial underlying medical disorders who are also taking several concurrent drugs. Patients with pre-existing hepatic problems should have periodic liver function tests done, especially during prolonged medication. If liver enzyme levels continue to rise or worsen, treatment should be stopped.
How to manage the interaction:
In patients with preexisting liver abnormalities, particularly during prolonged therapy, liver function tests should be done regularly. Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.
FLUCONAZOLE-0.5% W/WOther cardiac arrhythmias
Moderate
How does the disease interact with Flucos 150mg Powder:
The QT interval on the ECG has been shown to be prolonged by some azole antifungals. During postmarketing experience, there have been a few isolated incidences of QT prolongation and torsade de pointes; these reports typically involved critically ill patients with a number of complicating risk factors, including structural cardiac disease, electrolyte problems, and concurrent medicines. Patients with illnesses that could cause proarrhythmic symptoms should take these medications cautiously. It is best to avoid using drugs that could potentially enhance the risk of cardiotoxicity concurrently.
How to manage the interaction:
It should be administered with caution to patients with heart problems. Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.
The QT interval on the ECG has been shown to be prolonged by some azole antifungals. During postmarketing experience, there have been a few isolated incidences of QT prolongation and torsade de pointes; these reports typically involved critically ill patients with a number of complicating risk factors, including structural cardiac disease, electrolyte problems, and concurrent medicines. Patients with illnesses that could cause proarrhythmic symptoms should take these medications cautiously. It is best to avoid using drugs that could potentially enhance the risk of cardiotoxicity concurrently.
How to manage the interaction:
It should be administered with caution to patients with heart problems. Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.
FLUCONAZOLE-0.5% W/WCare involving dialysis
Moderate
How does the disease interact with Flucos 150mg Powder:
Hemodialysis effectively removes Flucos 150mg Powder from the body. Following three hours of dialysis, it has been demonstrated that plasma levels of Flucos 150mg Powder decrease by 50%. After hemodialysis, Flucos 150mg Powder should be taken.
How to manage the interaction:
Flucos 150mg Powder should be administered after hemodialysis.
Hemodialysis effectively removes Flucos 150mg Powder from the body. Following three hours of dialysis, it has been demonstrated that plasma levels of Flucos 150mg Powder decrease by 50%. After hemodialysis, Flucos 150mg Powder should be taken.
How to manage the interaction:
Flucos 150mg Powder should be administered after hemodialysis.
